Jupiter Topco’s Aktis Oncology AKTS Stock Holding History

Jupiter Topco’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.4M	Buy	+1,314,267	New	+$27M	0.02%	474

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Jupiter Topco's AKTS Position: Q2 2026 in Review

Jupiter Topco opened a new position in Aktis Oncology (AKTS) in Q2 2026: 1,314,267 shares worth $42.4M. The stake represents 0.02% of the portfolio and ranks #474 among its holdings.

106 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

Jupiter Topco held 1,314,267 shares of Aktis Oncology worth $42.4M as of Q2 2026.
Aktis Oncology was a new Jupiter Topco position in Q2 2026.
Aktis Oncology made up 0.02% of Jupiter Topco's portfolio in Q2 2026, its #474 holding.
106 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.